Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Lantheus Holdings, Inc., Myriad Genetics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Lantheus Holdings, Inc., Myriad Genetics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Lantheus Holdings, Inc., Myriad Genetics and Inc.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer’s disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Latest Health Care Equipment & Supplies and Lantheus Holdings, Inc., Myriad Genetics, Inc. Stock News

As of July 31, 2026, Lantheus Holdings, Inc. had a $6.5 billion market capitalization, compared to the Health Care Equipment & Supplies median of $337.2 million. Lantheus Holdings, Inc.’s stock is up 49.7% in 2026, down 4.9% in the previous five trading days and up 38.7% in the past year.

Currently, Lantheus Holdings, Inc.’s price-earnings ratio is 23.9. Lantheus Holdings, Inc.’s trailing 12-month revenue is $1.5 billion with a 18.0% net profit margin. Year-over-year quarterly sales growth most recently was 1.2%. Analysts expect adjusted earnings to reach $5.356 per share for the current fiscal year. Lantheus Holdings, Inc. does not currently pay a dividend.

As of July 31, 2026, Myriad Genetics, Inc. had a $273.6 million market cap, putting it in the 31st percentile of all stocks. Myriad Genetics, Inc.’s stock is down 53.5% in 2026, down 49% in the previous five trading days and down 29.38% in the past year.

Currently, Myriad Genetics, Inc. does not have a price-earnings ratio. Myriad Genetics, Inc.’s trailing 12-month revenue is $829.0 million with a -14.0% net profit margin. Year-over-year quarterly sales growth most recently was 2.3%. Analysts expect adjusted earnings to reach $0.080 per share for the current fiscal year. Myriad Genetics, Inc. does not currently pay a dividend.

How We Compare Lantheus Holdings, Inc., Myriad Genetics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Lantheus Holdings, Inc., Myriad Genetics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Lantheus Holdings, Inc., Myriad Genetics and Inc. Growth Grades

Company	Ticker	Growth
Lantheus Holdings, Inc.	LNTH	B
Myriad Genetics, Inc.	MYGN	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Lantheus Holdings, Inc. has a Growth Score of 69, which is Strong. Myriad Genetics, Inc. has a Growth Score of 39, which is Weak.

The Growth Grade Winner: Lantheus Holdings, Inc.

As you can clearly see from the Growth Grade breakdown above, Lantheus Holdings, Inc. has a more attractive growth grade than Myriad Genetics, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Lantheus Holdings, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Lantheus Holdings, Inc., Myriad Genetics and Inc.’s Quality Grades

Company	Ticker	Quality
Lantheus Holdings, Inc.	LNTH	A
Myriad Genetics, Inc.	MYGN	C

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Lantheus Holdings, Inc. has a Quality Score of 89, which is Very Strong. Myriad Genetics, Inc. has a Quality Score of 50, which is Average.

The Quality Grade Winner: Lantheus Holdings, Inc.

As you can clearly see from the Quality Grade breakdown above, Lantheus Holdings, Inc. has a better overall quality grade than Myriad Genetics, Inc.. For investors who are looking for companies with higher quality than others in the same industry, Lantheus Holdings, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Lantheus Holdings, Inc., Myriad Genetics and Inc.’s Momentum Grades

Company	Ticker	Momentum
Lantheus Holdings, Inc.	LNTH	B
Myriad Genetics, Inc.	MYGN	D

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Lantheus Holdings, Inc. has a Momentum Score of 77, which is Strong. Myriad Genetics, Inc. has a Momentum Score of 27, which is Weak.

The Momentum Grade Winner: Lantheus Holdings, Inc.

As you can clearly see from the Momentum Grade breakdown above, Lantheus Holdings, Inc. is considered to have stronger momentum compared to Myriad Genetics, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Lantheus Holdings, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Lantheus Holdings, Inc., Myriad Genetics and Inc. Grades

In addition to Quality, Growth and Momentum, A+ Investor also provides grades for Value and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Lantheus Holdings, Inc., Myriad Genetics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Lantheus Holdings, Inc., Myriad Genetics or Inc. Stock?

Overall, Lantheus Holdings, Inc. stock has a Growth Score of 69, Momentum Score of 77 and Quality Score of 89.

Myriad Genetics, Inc. stock has a Growth Score of 39, Momentum Score of 27 and Quality Score of 50.

Comparing Lantheus Holdings, Inc., Myriad Genetics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.